337,161 Shares in Zymeworks Inc. (NYSE:ZYME) Purchased by Schroder Investment Management Group

Schroder Investment Management Group acquired a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 337,161 shares of the company's stock, valued at approximately $4,892,000. Schroder Investment Management Group owned approximately 0.49% of Zymeworks as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. AlphaQuest LLC boosted its stake in shares of Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock valued at $41,000 after buying an additional 2,324 shares during the period. FMR LLC lifted its stake in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after buying an additional 1,525 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Zymeworks in the fourth quarter valued at approximately $151,000. New York State Common Retirement Fund increased its holdings in shares of Zymeworks by 42.7% in the fourth quarter. New York State Common Retirement Fund now owns 13,371 shares of the company's stock valued at $196,000 after purchasing an additional 4,000 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in shares of Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock valued at $201,000 after purchasing an additional 2,216 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.

Insider Buying and Selling

In other Zymeworks news, Director Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $14.01 per share, for a total transaction of $546,796.29. Following the completion of the transaction, the director now owns 15,578,732 shares of the company's stock, valued at $218,258,035.32. This represents a 0.25 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders have acquired 1,613,394 shares of company stock worth $19,805,225. 1.92% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ZYME has been the topic of a number of recent analyst reports. Citigroup upped their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. Lifesci Capital initiated coverage on Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Wells Fargo & Company upped their target price on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. HC Wainwright upped their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Finally, JPMorgan Chase & Co. raised Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price on the stock in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Zymeworks presently has an average rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Trading Down 6.6 %

Shares of NYSE:ZYME traded down $0.66 on Thursday, hitting $9.34. The company had a trading volume of 195,732 shares, compared to its average volume of 613,361. The business has a 50 day moving average of $12.86 and a 200 day moving average of $13.60. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70. The company has a market cap of $649.85 million, a PE ratio of -6.23 and a beta of 1.18.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.